Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
Rujipas Sirijatuphat, Weerawat Manosuthi, Suvimol Niyomnaitham, Andrew Owen, Katherine K Copeland, Lantharita Charoenpong, Manoch Rattanasompattikul, Surakameth Mahasirimongkol, MD Kulkanya Chokephaibulkit
doi:10.1101/2022.06.06.22275902
We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia development. PCR-confirmed SARS-CoV-2-infected patients without pneumonia were enrolled (2:1) within 10 days of symptomatic onset into FPV and control arms. The former received 1800 mg FPV twice-daily (BID) on Day 1 and 800 mg BID 5-14 days thereafter until negative viral detection, while the latter received supportive care only. The primary endpoint was time to clinical improvement, which was defined by a reduced National Early Warning Score (NEWS) or score of <1. 62 patients (41 female) comprised the FPV arm (median age: 32 years, median BMI: 22 kg/m²) and 31 patients (19 female) comprised the control arm (median age: 28 years, median BMI: 22 kg/m². The median time to sustained clinical improvement by NEWS was 2 vs 14 days for FPV and control arms respectively (adjusted hazard ratio (aHR) of 2.77, 95% CI 1.57-4.88, P <0.001). The FPV arm also had significantly higher likelihoods of clinical improvement within 14 days after enrolment by NEWS (79% vs 32% respectively, P <0.001), particularly female patients (aOR 6.35, 95% CI 1.49-27.07, P <0.001). 8 (12.9%) and 7 (22.6%) patients in FPV and control arms developed mild pneumonia at a median (range) 6.5 (1-13) and 7 (1-13) days after treatment, respectively (P = 0.316); all recovered well without complications. We can conclude that early treatment of FPV in symptomatic COVID-19 patients without pneumonia was associated with faster clinical improvement.
Declaration of Interest Statement AO is a Director of Tandem Nano Ltd and co-inventor of patents relating to drug delivery. AO
References
Ader, Bouscambert-Duchamp, Hites, Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial, Lancet Infect Dis
Agrawal, Raju, Udwadia, Favipiravir: A new and emerging antiviral option in COVID-19, Med J Armed Forces India
Alene, Yismaw, Assemie, Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis, PLoS One
Bai, Mu, Kargbo, Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014, Clin Infect Dis
Baranovich, Wong, Armstrong, T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, J Virol
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, New England Journal of Medicine
Brophy, Molnupiravir's authorisation was premature
Cai, Yang, Liu, Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering
Chen, Chao, Lai, Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients, J Infect
Chuah, Chow, Hor, Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial, Clin Infect Dis
Deng, Yang, Yang, Evaluation of favipiravir in the treatment of COVID-19 based on the real-world, Expert Rev Anti Infect Ther
Do, National Early Warning Score, National Clinical Guideline
Doi, Hibino, Hase, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19, Antimicrob Agents Chemother
Eroglu, Toprak, Overview of favipiravir and remdesivir treatment for COVID-19
Fischer, Eron, Holman, A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med
Fujifilm Toyama, Co, Notice of The New Drug Application Approval of "AVIGAN® Tablet 200mg
Fujii, Ibe, Ishigo, Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients, Journal of Infection and Chemotherapy
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci
Ghasemnejad-Berenji, Pashapour, Favipiravir and COVID-19: A Simplified Summary, Drug Res (Stuttg)
Gottlieb, Vaca, Paredes, Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N Engl J Med
Gowen, Wong, Jung, In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections, Antimicrob Agents Chemother
Hassanipour, Arab-Zozani, Amani, The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep
Holubar, Subramanian, Purington, Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial, Clin Infect Dis
Ivashchenko, Dmitriev, Vostokova, AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin Infect Dis
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Kelleni, Tocilizumab, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment, SN Compr Clin Med
Ko, Jeon, Ryu, Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells, J Med Virol
Kumari, Rawat, Saha, Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update, Curr Pharmacol Rep
Kutsuna, Coronavirus disease
Lu, Chen, Lee, Potential therapeutic agents against COVID-19: What we know so far, J Chin Med Assoc
Manabe, Kambayashi, Akatsu, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis
Manosuthi, Jeungsmarn, Okada, Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir, Jpn J Infect Dis
Mendenhall, Russell, Smee, Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever, PLoS Negl Trop Dis
Nalbandian, Sehgal, Gupta, Post-acute COVID-19 syndrome, Nat Med
Oestereich, Lüdtke, Wurr, Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res
Organization, WHO Coronavirus (COVID-19) Dashboard
Pertinez, Rajoli, Khoo, Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2, J Antimicrob Chemother
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J Virus Erad
Pongpirul, Wiboonchutikul, Charoenpong, Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand, PLoS Negl Trop Dis
Prakash, Singh, Kaur, Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients, Indian J Pharmacol
Prasithsirikul, Pongpirul, Sakornsakolpat, Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand, Asian Biomedicine
Reddy, Lai, Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options, Chembiochem
Sawanpanyalert, Sirijatuphat, Sangsayunh, Assessement of outcomes following implementation of antiviral treatment guidelines for COVID-19 during the first wave in Thailand, Southeast Asian Journal of Tropical Medicine and Public Health
Seneviratne, Abeysuriya, Mel, Favipiravir in COVID-19, International Journal of Progressive Sciences and Technologies
Sheahan, Sims, Zhou, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci Transl Med
Shinada, Sato, Moriyama, Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir, Viruses
Shrestha, Budhathoki, Khadka, Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virol J
Siemieniuk, Bartoszko, Ge, Drug treatments for covid-19: living systematic review and network meta-analysis, Bmj
Srinivas, Sacha, Koval, Antivirals for COVID-19, Cleaveland Clinical Journal of Medicine
Thorlund, Sheldrick, Mills, Molnupiravir for Covid-19 in Nonhospitalized Patients
Udwadia, Singh, Barkate, Efficacy and safety of favipiravir, an oral RNAdependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wei, Moradkhani, Hezaveh, Evaluating the Treatment with Favipiravir in Patients Infected by COVID-19: A Systematic Review and Meta-analysis International Journal of Scientific Research in Dental, and Medical Sciences
Yanai, Favipiravir: A Possible Pharmaceutical Treatment for COVID-19, Journal of Endocrinology & Metabolism
Özlüşen, Kozan, Akcan, Effectiveness of favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis
